A study of double-labeled retinal ganglion cells from the superior colliculus in the developing albino rat

VEGF-A165b is an endogenous neuroprotective splice isoform of vascular endothelial growth factor A in vivo and in vitro

Vascular endothelial growth factor (VEGF) A is generated as two isoform families by alternative RNA splicing, represented by VEGF-A165a and VEGF-A165b. These isoforms have opposing actions on vascular permeability, angiogenesis, and vasodilatation. The proangiogenic VEGF-A165a isoform is neuroprotective in hippocampal, dorsal root ganglia, and retinal neurons, but its propermeability, vasodilatatory, and angiogenic properties limit its therapeutic usefulness. In contrast, a neuroprotective effect of endogenous VEGF-A165b on neurons would be advantageous for neurodegenerative pathologies. Endogenous expression of human and rat VEGF-A165b was detected in hippocampal and cortical neurons. VEGF-A165b formed a significant proportion of total VEGF-A in rat brain. Recombinant human VEGF-A165b exerted neuroprotective effects in response to multiple insults, including glutamatergic excitotoxicity in hippocampal neurons, chemotherapy-induced cytotoxicity of dorsal root ganglion neurons, and retinal ganglion cells (RGCs) in rat retinal ischemia-reperfusion injury in vivo. Neuroprotection was dependent on VEGFR2 and MEK1/2 activation but not on p38 or phosphatidylinositol 3-kinase activation. Recombinant human VEGF-A165b is a neuroprotective agent that effectively protects both peripheral and central neurons in vivo and in vitro through VEGFR2, MEK1/2, and inhibition of caspase-3 induction. VEGF-A165b may be therapeutically useful for pathologies that involve neuronal damage, including hippocampal neurodegeneration, glaucoma diabetic retinopathy, and peripheral neuropathy. The endogenous nature of VEGF-A165b expression suggests that non-isoform-specific inhibition of VEGF-A (for antiangiogenic reasons) may be damaging to retinal and sensory neurons.

Retrograde fluorescent double-labeling study of bilaterally projecting retinal ganglion cells in albino rats at different stages of development

Injection of the fluorescent tracers 10% Evans blue (EB) and 4% fluoro-gold (FG) into the right and the left dorsal lateral geniculate nucleus, respectively, of albino rats at different stages of development demonstrated the presence of double-labeled retinal ganglion cells that projected bilaterally into both the dorsal lateral geniculate nuclei (dLGN). Findings confirmed that the distribution of these double-labeled cells was gradually reduced after birth, being confined to the peripheral temporoventral quarter (temporal-ventral crescent) of the retina after postnatal day 15. We estimated the proportion of double-labeled cells to total labeled cells in the same area at different stages of development (0-90 days); values ranged from 35.3% in the neonate to 5.27% in the adult rat which suggests that the majority of double-labeled cells and/or their axons were lost early in development. That a small number of ganglion cells were observed to project bilaterally in the adult rats suggested that these cells conduct the same visual information to both hemispheres throughout the animal's life.

A retrograde double-labeling study of uni- and bilaterally projecting retinal ganglion cells that project to the superior colliculi after unilateral eye removal at birth in the albino rat

By injecting Fluoro-Gold and Evans-Blue into the right and left superior colliculi of the normal adult albino rats, bilaterally projecting retinal ganglion cells were labeled in the ventrotemporal crescent accounting for 37.9% of all the labeled cells, whereas in 0- and 5-day unilaterally enucleated rats these were found in the lower half of the retina accounting for 64.8% and 80.6%, respectively. Furthermore, they tended to have larger somata (type I cells).